Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts, Cairo, Egypt.
Department of Pharmacology, Faculty of Pharmacy, October University for Modern Sciences and Arts, Cairo, Egypt.
Pharm Dev Technol. 2021 Dec;26(10):1035-1050. doi: 10.1080/10837450.2021.1980009. Epub 2021 Sep 23.
The current work aims to utilize a quality by design (QbD) approach to develop and optimize nanovesicular carriers of a hydrophobic drug. Rosuvastatin calcium was used as a model drug, which suffers poor bioavailability. Several tools were used in the risk assessment study as Ishikawa diagrams. The critical process parameters (CPP) were found to be the particle size, polydispersity index, zeta potential, and entrapment efficiency. A factorial design was used in risk analysis, which was complemented with an artificial neural network (ANN); to assure its accuracy. A design space was established, with an optimized nanostructured lipid carrier formula containing 3.2% total lipid content, 0.139% surfactant, and 0.1197 mg % drug. The optimized formula showed a sustained drug release up to 72 h. It successfully lowered each of the total cholesterol, low-density lipoprotein, and triglycerides and elevated the high-density lipoprotein levels, as compared to the standard drug. Thus, the concurrent use of the factorial design with ANN using the QbD approach permitted the exploration of the experimental regions for a successful nanovesicular carrier formulation and could be used as a reference for many nanostructured drug delivery studies during their pharmaceutical development and product manufacturing.
本工作旨在采用质量源于设计(QbD)方法开发和优化疏水性药物的纳米囊载体。以瑞舒伐他汀钙为模型药物,其生物利用度较差。在风险评估研究中使用了几种工具,如石川图。关键工艺参数(CPP)被发现是粒径、多分散指数、Zeta 电位和包封效率。使用析因设计进行风险分析,并辅以人工神经网络(ANN)以确保其准确性。建立了设计空间,包含 3.2%总脂质含量、0.139%表面活性剂和 0.1197mg%药物的优化纳米结构脂质载体配方。优化配方显示出长达 72 小时的药物持续释放。与标准药物相比,它成功降低了总胆固醇、低密度脂蛋白和甘油三酯的水平,并提高了高密度脂蛋白的水平。因此,使用 QbD 方法的析因设计与 ANN 的联合使用允许对成功的纳米囊载体配方进行实验区域的探索,并可作为许多纳米结构药物传递研究在药物开发和产品制造过程中的参考。